

Press Release 31 March 2016

## **Infant Bacterial Therapeutics receives Rare Pediatric Disease Designation from FDA for drug candidate**

Infant Bacterial Therapeutics AB (publ) ("IBT") announces that the U.S. Food and Drug Administration (FDA) has awarded IBT Rare Pediatric Disease Designation for its drug candidate IBP-9414, intended for the prevention necrotizing enterocolitis in premature infants.

Rare Pediatric Disease Designation is intended to encourage development of new drug and biological products for the prevention and treatment of certain rare pediatric diseases. Having obtained the Rare Pediatric Disease Designation, FDA may award IBT a priority review voucher. A priority review voucher means that FDA ought to handle a drug application faster than normal.

Staffan Strömberg, Chief Executive Officer of IBT, commented, "The fact that FDA has given IBP-9414 Rare Pediatric Disease Designation, confirms how important it is to reach our goal that fewer premature babies shall be affected by the deadly disease necrotizing enterocolitis, whilst at the same time this can reduce the time for this product to reach the market."

**For additional information please contact**

Staffan Strömberg, CEO, phone: +46 8 410 145 55

Peter Rothschild, Chairman of the Board, phone: +46 8 410 145 55

Infant Bacterial Therapeutics AB  
Bryggargatan 10  
111 21 Stockholm  
Phone: +46 8 410 145 55  
[info@ibtherapeutics.com](mailto:info@ibtherapeutics.com)

Infant Bacterial Therapeutics AB ("IBT") is a pharmaceutical company based in Stockholm that develops drugs that meet the needs of the premature infant. IBT's current focus is on clinical development of IBP-9414, a drug candidate containing *Lactobacillus reuteri*, in the prevention of necrotizing enterocolitis ("NEC"), a fatal disease that affects premature infants. IBT is listed on NASDAQ First North.

[www.ibtherapeutics.com](http://www.ibtherapeutics.com)